5 Allergic Asthma and Aging (original) (raw)

Abstract

Bronchial Asthma-Emerging Therapeutic Strategies 90 Elderly asthmatic patients mainly include those who have acquired the disease during childhood or adolescence and whose disease has progressed over time or is recurrent after periods of remission (elderly asthmatics, long life), but the first manifestations of asthma can occur even in late adulthood or after 65 years of age (the elderly, asthmatics, late-onset). These considerations, taken in isolation, have resulted in asthma being under-diagnosed and under-treated in elderly patients, which may be due to diagnostic misclassification. Underestimation of the prevalence of asthma may be due to confusion with COPD. In this chapter, after describing the basics of atopy and immune alteration of the immune system in the elderly, we will examine the flow characteristics of the pathophysiology of asthma and COPD, establish the basis for correct diagnosis of asthma, highlighting the confounding factors of diagnosis, and the importance of monitoring the clinical course, identifying areas for improvement. 2. Definition of asthma Scientific knowledge has changed the definition of bronchial asthma and is now defined as r e p o r t e d b y t h e N a t i o n a l I n s t i t u t e s o f H e a l t h (N I H) [ 1 ]. A s t h m a i s d e f i n e d a s a n inflammatory disorder of the airway associated with airflow obstruction and bronchial hyper-responsiveness, This definition replaces the previous definition of asthma in which only the airflow obstruction and the bronchial hyper-responsiveness was emphasized [2]. 2.1 Epidemiology The overall prevalence of asthma in children and adults varies in European countries, with estimates of 15%-18% in the United Kingdom, 7% in France and Germany, 4.4 Italy and of 1.9 in Albania [3]. Long considered a disease of childhood or young adulthood, its prevalence is now known to be similar in older people [4]. The incidence of newly diagnosed asthma in patients ≥ 65 years is 0.1%/years in a population based study done on Rochester residents [5]. Asthma may persist from childhood or have its onset in adult life. The primary variable for persistence and severity of asthma identified in longitudinal studies is the severity in childhood. However, common sense and everyday experience tell us that continued exposure to relevant indoor allergens is also important [6,7]. The studies also suggest that sensitization and exposure to outdoor allergens, result in more persistent and severe asthma [8]. The presence of atopy increases the incidence of asthma in children and may also increase the incidence in young adults. A cohort of college students evaluated for hay fever or asthma were followed up 23 years later. At the age of 40 years, about half of subjects who had asthma as freshmen continued to have asthma. Of these subjects, half (a quarter of the entire group) reported that they continued to have about the same frequency and severity of symptoms; very few were worse. During these 23 years, 5.2% of subjects who did not have asthma as freshmen developed asthma subsequently; the yearly incidence rate was 0.23%. The presence of positive skin test results or hay fever as freshmen did not affect the incidence of new cases of asthma as these subjects www.intechopen.com Allergic Asthma and Aging 91 grew older. Unfortunately, skin tests were not performed at the 23-year follow-up of middleaged adults, so it is not known whether these new case of asthma were allergic [9]. The incidence of asthma is the same in patients age 65 to 84 years as it is in younger adults [10]. However the disease may be more likely to persist and progress in severity. A crosssectional study of 242 patients with asthma age 65 and older found that 80% had irreversible obstruction; 20% of them were unable to achieve an FEV1 greater than 50% predicted. The authors concluded that only a part of this irreversibility is the result of airway remodeling from asthmatic inflammation [10]. The diagnosis of asthma may be more difficult in the elderly because of the high prevalence of other disorders that can have similar symptoms, and because airflow obstruction is often caused by chronic obstructive pulmonary disease [11].

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (147)

  1. Fletcher CM, Pride NB. Definitions of emphysema, chronic bronchitis, asthma, and airflow obstruction: 25 years on from the Ciba symposium. Thorax. 1984; 39: 81-5.
  2. NIH. NIH Expert Panel Report 2. Clinical practice guidelines: guidelines for the diagnosis and management of asthma. NIH Publication 1997: 97-4051 [online].
  3. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469-78.
  4. Cassino C, Berger KI, Goldring RM, Norman RG, Kammerman S, Ciotoli C, Reibman J. Duration of asthma and physiologic outcomes in elderly nonsmokers. Am J Respir Crit Care Med. 2000; 162: 1423-8.
  5. Bauer BA, Reed CE, Yunginger JW, Wollan PC, Silverstein MD. Incidence and outcomes of asthma in the elderly. A population-based study in Rochester, Minnesota. Chest. 1997; 111: 303-10.
  6. Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol 2002;109:189-94.
  7. Townley RG, Ryo UY, Kolotkin BM, Kang B. Bronchial sensitivity to methacholine in current and former asthmatic and allergic rhinitis patients and control subjects. J Allergy Clin Immunol. 1975 Dec;56(6):429-42.
  8. Di Lorenzo G, Mansueto P, Melluso M, et al. Non-specific air way hyperresponsiveness in mono-sensitive Sicilian patients with allergic rhinitis. Its relationship to total serum IgE levels and blood eosinophils during and out of the pollen season. Clin Exp Allergy. 1997; 27: 1052-9.
  9. Settipane GA, Greisner WA III, Settipane RJ. Natural history of asthma: a 23-year followup of college students. Ann Allergy Asthma Immunol 2000;84:499-503.
  10. Reed CE. The natural history of asthma in adults: the problem of irreversibility. J Allergy Clin Immunol 1999;103:539-47.
  11. Dow L, Fowler L, Phelps L, Waters K, Coggon D, Kinmonth AL, Holgate ST. Prevalence of untreated asthma in a population sample of 6000 older adults in Bristol, UK. Thorax. 2001; 56: 472-6.
  12. Ho SF, O'Mahony MS, Steward JA, et al. Dyspnoea and quality of life in older people at home. Age Ageing 2001; 30: 155-9
  13. Wolfenden LL, Diette GB, Krishnan JA, et al. Lower physician estimate of underlying asthma severity leads to undertreatment. Arch Intem Med 2003; 163: 231-6
  14. Van den Boom, van Schayck CP, Rutten-van Molken PMH, et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population. Am J Respir Crit Care Med 1998;158:1730-8.
  15. Connolly MJ, Crowley JJ, Charan NB, Nielson CP, Vestal RE. Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax. 1992; 47: 410-3.
  16. Weiner P, Magadle R, Waizman J, Weiner M, Rabner M, Zamir D. Characteristics of asthma in the elderly. Eur Respir J. 1998; 12: 564-8.
  17. Ulrik CS, Lange P. Decline of lung function in adults with bronchial asthma. Am J Respir Crit Care Med. 1994 Sep;150(3):629-34.
  18. Lieberman J, Schleissner L, Tachiki KH, Kling AS. Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol Aging. 1995; 16: 747-53.
  19. Marks GB, Poulos LM, Jenkins CR, Gibson PG. Asthma in older adults: a holistic, person-centred and problem-oriented approach. Med J Aust. 2009; 191: 197-9.
  20. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008; 31: 204-12.
  21. National Institute for Clinical Excellence (NICE). Management of chronic obstructive pulmonary disease in adults in primary and secondary care (clinical guideline 12). London: NICE; 2004 [online]. Available from URL: http://guidance.nice.org.uk/CG101/Guidance/pdf/English [Accessed 2010 June 23]
  22. Di Lorenzo G, Mansueto P, Ditta V, Esposito-Pellitteri M, Lo Bianco C, Leto-Barone MS, D'Alcamo A, Farina C, Di Fede G, Gervasi F, Caruso C, Rini G. Similarity and differences in elderly patients with fixed airflow obstruction by asthma and by chronic obstructive pulmonary disease. Respir Med. 2008; 102: 232-8.
  23. Ormiston TM, Salpeter SR. Beta-blocker use in patients with congestive heart failure and concomitant obstructive airway disease: moving from myth to evidence-based practice. Heart Fail Monit. 2003; 4: 45-54.
  24. Sirithunyanont C, Leowattana W, Sukumalchantra Y, Chaisupamonkollarp S, Watanawaroon S, Chivatanaporn B, Bhuripanyo K, Mahanonda N. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases. J Med Assoc Thai. 2003; 86 (Suppl 1): S87-95.
  25. Pasina L, Nobili A, Tettamanti M, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Mannucci PM; on behalf of REPOSI Investigators. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011; 22: 205-210.
  26. Marik PE. Pulmonary aspiration syndromes. Curr Opin Pulm Med. 2011 Feb 9. [Epub ahead of print].
  27. Korycki J, Dobrowolski J. Primary tracheal cancer treated by restoring the patency. Wiad Lek. 1968; 21: 1239-42.
  28. Harada K, Noguchi T, Fujiwara S, Moriyama H, Kitano S, Kawahara K. Complete response in an elderly patient with advanced gastric cancer treated with TS-1. Gan To Kagaku Ryoho. 2007; 34: 427-30.
  29. Mamlouk MD, vanSonnenberg E, Gosalia R, Drachman D, Gridley D, Zamora JG, Casola G, Ornstein S. Pulmonary embolism at CT angiography: implications for appropriateness, cost, and radiation exposure in 2003 patients. Radiology. 2010; 256: 625-32.
  30. Lucassen WA, Douma RA, Toll DB, Büller HR, van Weert HC. Excluding pulmonary embolism in primary care using the Wells-rule in combination with a point-of care D-dimer test: a scenario analysis. BMC Fam Pract. 2010;11: 64.
  31. Lin CF, Wang CY, Bai CH. Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening study. Drugs Aging. 2011; 28: 219-25.
  32. Erdmann E. Safety and tolerability of beta-blockers: prejudices & reality. Indian Heart J. 2010; 62: 132-5.
  33. Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy Asthma Immunol Res. 2011; 3: 3-10.
  34. Irwin RS. Unexplained cough in the adult. Otolaryngol Clin North Am. 2010b; 43: 167- 80.
  35. Di Lorenzo G, Morici G, Drago A, Pellitteri ME, Mansueto P, Melluso M, Norrito F, Squassante L, Fasolo A. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group. Clin Ther. 1998; 20: 1130-48.
  36. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2009. Available from: www.goldcopd.com. Accessed 2010 May 12.
  37. von Scheele I, Larsson K, Dahlén B, Billing B, Skedinger M, Lantz AS, Palmberg L. Toll- like receptor expression in smokers with and without COPD. Respir Med. 2011; 105:1222-30.
  38. Bafadhel M, Umar I, Gupta S, Raj JV, Vara DD, Entwisle JJ, Pavord ID, Brightling CE, Siddiqui S. The role of computed tomography in multi-dimensional phenotyping of chronic obstructive pulmonary disease. Chest. 2011 Mar 31.
  39. Papadopoulos G, Vardavas CI, Limperi M, Linardis A, Georgoudis G, Behrakis P. Smoking cessation can improve quality of life among COPD patients: Validation of the clinical COPD questionnaire into Greek. BMC Pulm Med. 2011; 11: 13.
  40. Deslee G, Woods JC, Moore CM, Liu L, Conradi SH, Milne M, Gierada DS, Pierce J, Patterson A, Lewit RA, Battaile JT, Holtzman MJ, Hogg JC, Pierce RA. Elastin expression in very severe human COPD. Eur Respir J. 2009; 34: 324-31.
  41. Peacock JL, Anderson HR, Bremner SA, Marston L, Seemungal TA, Strachan DP, Wedzicha JA. Outdoor air pollution and respiratory health in patients with COPD. Thorax. 2011; 66: 591-6.
  42. Perez-Padilla R, Schilmann A, Riojas-Rodriguez H. Respiratory health effects of indoor air pollution. Int J Tuberc Lung Dis. 2010 Sep;14(9):1079-86.
  43. Roche N, Gaillat J, Garre M, Meunier JP, Lemaire N, Bendjenana H. Acute respiratory illness as a trigger for detecting chronic bronchitis in adults at risk of COPD: a primary care survey. Prim Care Respir J. 2010; 19 :371-7.
  44. Sifers RN. Intracellular processing of alpha1-antitrypsin. Proc Am Thorac Soc. 2010; 7: 376-80.
  45. Bals R. Alpha-1-antitrypsin deficiency. Best Pract Res Clin Gastroenterol. 2010; 24: 629- 33.
  46. Sona A, Maggiani G, Astengo M, Comba M, Chiusano V, Isaia G, Merlo C, Pricop L, Quagliotti E, Moiraghi C, Fonte G, Bo M. Determinants of recourse to hospital treatment in the elderly. Eur J Public Health. 2011 Mar 31.
  47. Delage A, Tillie-Leblond I, Cavestri B, Wallaert B, Marquette CH. Cryptogenic hemoptysis in chronic obstructive pulmonary disease: characteristics and outcome. Respiration. 2010; 80: 387-92.
  48. Barker AF. Bronchiectasis. N Engl J Med. 2002; 346: 1383-93.
  49. Hancock DB, London SJ; CHARGE Pulmonary Function Working Group. Determinants of lung function, COPD, and asthma. N Engl J Med. 2011; 364: 86-7.
  50. Wong R, Sibley KM, Hudani M, Roeland S, Visconti M, Balsano J, Hill K, Brooks D. Characteristics of people with chronic lung disease who rest during the six-minute walk test. Arch Phys Med Rehabil. 2010; 91: 1765-9.
  51. Baldacci S, Omenaas E, Oryszczyn MP. Allergy markers in respiratory epidemiology. Eur Respir J. 2001; 17: 773-90.
  52. Terho EO, Koskenvuo M, Kaprio J. Atopy: a predisposing factor for chronic bronchitis in Finland. J Epidemiol Community Health. 1995; 49: 296-8.
  53. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:418- 24.
  54. Barnes PJ. Pathophysiology of asthma. Br J Clin Pharmacol 1996; 42:3-10.
  55. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53:129-136.
  56. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma and normal subjects. Am J Respir Crit Care Med 1997; 155:449-453
  57. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995; 152:1262- 1267.
  58. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008; 8: 183-92.
  59. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2009; 41: 631-8.
  60. Di Lorenzo G, Pacor ML, Esposito Pellitteri M, et al. A study of age-related IgE pathophysiological changes. Mech Ageing Dev. 2003; 124: 445-8.
  61. Barnes PJ, Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.
  62. Cantin AM. Cellular response to cigarette smoke and oxidants: adapting to survive. Proc Am Thorac Soc. 2010; 7: 368-75.
  63. Royce SG, Tang ML. The effects of current therapies on airway remodeling in asthma and new possibilities for treatment and prevention. Curr Mol Pharmacol. 2009; 2: 169-81.
  64. Demkow U, van Overveld FJ. Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatment. Eur J Med Res. 2010; 15 (Suppl 2): 27-35.
  65. Tuder RM, Janciauskiene SM, Petrache I. Lung disease associated with alpha1- antitrypsin deficiency. Proc Am Thorac Soc. 2010; 7: 381-6.
  66. Lagente V, Boichot E. Role of matrix metalloproteinases in the inflammatory process of respiratory diseases. J Mol Cell Cardiol. 2010; 48: 440-4.
  67. Folkerts, G., Kloek, J., Muijsers, R.B.R., Nijkamp, F.P. Reactive nitrogen and oxygen species in airway inflammation. Eur. J. Pharmacol.2001; 429: 251-262.
  68. Rahman, I., MacNee, W., 2000. Oxidative stress and regulation of glutathione synthesis in lung inflammation. Eur. Respir. J. 2000; 16: 534-554.
  69. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010; 105: 99-106.
  70. Bousquet J, Chanez P, Campbell AM, Vignola Godard P. Cellular inflammation in asthma. Clin Exp Allergy. 1995; 25 (Suppl 2): 39-42.
  71. Spanevello A, Vignola AM, Bonanno A, Confalonieri M, Crimi E, Brusasco V. Effect of methacholine challenge on cellular composition of sputum induction. Thorax. 1999; 54: 37-9.
  72. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004; 202: 175-90.
  73. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest. 2005; 127: 1312-26.
  74. Lopez-Souza N, Favoreto S, Wong H, Ward T, Yagi S, Schnurr D, Finkbeiner WE, Dolganov GM, Widdicombe JH, Boushey HA, Avila PC. In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. J Allergy Clin Immunol. 2009; 123: 1384-90.e2.
  75. Trogdon JG, Nurmagambetov TA, Thompson HF. The economic implications of influenza vaccination for adults with asthma. Am J Prev Med. 2010; 39: 403-10.
  76. Solana R, Pawelec G. Molecular and cellular basis of immunosenescence. Mech Ageing Dev. 1998 May 15;102(2-3):115-29.
  77. Tillett HE, Smith JW, Clifford RE. Excess morbidity and mortality associated with influenza in England and Wales. Lancet. 1980; 1: 793-5.
  78. Candore G, Di Lorenzo G, Mansueto P, et al. Prevalence of organ-specific and non organ-specific autoantibodies in healthy centenarians. Mech Ageing Dev. 1997; 94:
  79. Derhovanessian E, Solana R, Larbi A, Pawelec G. Immunity, ageing and cancer.Immun Ageing. 2008; 5:11.
  80. Colonna-Romano G, Akbar AN, Aquino A. et al. Impact of CMV and EBV seropositivity on CD8 T lymphocytes in an old population from West-Sicily. Exp Gerontol. 2007; 42: 995-1002.
  81. Lio D, Candore G, Cigna D, et al. . In vitro T cell activation in elderly individuals: failure in CD69 and CD71 expression. Mech Ageing Dev. 1996; 89: 51-8.
  82. Candore G, Di Lorenzo G, Caruso C, et al. The effect of age on mitogen responsive T cell precursors in human beings is completely restored by interleukin-2. MechAgeing Dev. 1992; 63: 297-307.
  83. Candore G, Di Lorenzo G, Melluso M, Cigna D, Colucci AT, Modica MA, Caruso C. gamma-Interferon, interleukin-4 and interleukin-6 in vitro production in old subjects. Autoimmunity. 1993; 16: 275-80.
  84. Lio D, D'Anna C, Scola L, Di Lorenzo G, Colombo A, Listì F, Balistreri CR, Candore G, Caruso C. Interleukin-5 production by mononuclear cells from aged individuals: implication for autoimmunity. Mech Ageing Dev. 1999; 106: 297-304.
  85. Potestio M, Caruso C, Gervasi F, et al. Apoptosis and ageing. Mech Ageing Dev. 102: 221-37.
  86. Colonna-Romano G, Aquino A, Bulati M, Di Lorenzo G, Listì F, Vitello S, Lio D, Candore G, Clesi G, Caruso C. Memory B cell subpopulations in the aged. Rejuvenation Res. 2006; 9:149-52.
  87. Doria G, Dagostaro G, Poretti A. Age-Dependent Variations of Antibody Avidity. Immunology. 1978; 35: 601-611.
  88. Intonazzo V, La Rosa G, Di Lorenzo G, Sferlazzo A, Perna AM, Crescimanno G, Ingrassia, A. Immune response to a subunit trivalent influenza vaccine. Igiene Moderna. 1996; 96: 800-810.
  89. Di Lorenzo G, Balistreri CR, Candore G, Cigna D, Colombo A, Romano GC, Colucci AT, Gervasi F, Listì F, Potestio M, Caruso C. Granulocyte and natural killer activity in the elderly. Mech Ageing Dev. 1999; 108: 25-38.
  90. Lio D, D'Anna C, Scola L, Di Lorenzo G, Colombo A, Listì F, Balistreri CR, Candore G, Caruso C. Interleukin-5 production by mononuclear cells from aged individuals: implication for autoimmunity. Mech Ageing Dev. 1999; 106: 297-304.
  91. Caruso C, Candore G, Cigna D, DiLorenzo G, Sireci G, Dieli F, Salerno A. Cytokine production pathway in the elderly. Immunol Res. 1996; 15: 84-90.
  92. Pawelec G, Rehbein A, Haehnel K, Merl A and Adibzadeh M. Human T-cell clones as a model for immunosenescence. Immunol Rev 1997; 160: 31-43.
  93. Pawelec G, Mariani E, Bradley B, Solana R. Longevity in vitro of human CD4+ T helper cell clones derived from young donors and elderly donors, or from progenitor cells: age-associated differences in cell surface molecule expression and cytokine secretion. Biogerontology. 2000; 1: 247-54.
  94. Sitar DS, Aoki FY, Warren CP, Knight A, Grossman RF, Alexander M, Soliman S. A placebo-controlled dose-finding study with bambuterol in elderly patients with asthma. Chest. 1993; 103: 771-6.
  95. Horiguchi T, Tachikawa S, Kondo R, Miyazaki J, Shiga M, Hirose M, Kobayashi K, Hayashi N, Ohira D, Nasu T, Otake Y, Hata H. Comparative evaluation of the leukotriene receptor antagonist pranlukast versus the steroid inhalant fluticasone in the therapy of aged patients with mild bronchial asthma. Arzneimittelforschung. 2007; 57: 87-91.
  96. Busse PJ, Kilaru K. Complexities of diagnosis and treatment of allergic respiratory disease in the elderly. Drugs Aging. 2009; 26: 1-22.
  97. Braman SS, Hanania NA. Asthma in older adults. Clin Chest Med. 2007; 28: 685-702.
  98. Braman SS. Drug treatment of asthma in the elderly. Drugs 1996;51:415-23.
  99. Djukanović R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, Howarth PH, Holgate ST. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 1992; 145: 669-74.
  100. Boardley JE, Carey RA, Harvey AM Preliminary observations on the effect of adrenocorticotropic hormone in allergic diseases. Bull. Johns. Hopkins. Hosp. 1949: 85: 396-410.
  101. Medical Research Council. Controlled trial of effects of cortisone acetate in status asthmaticus; report to the Medical Research Council by the subcommittee on clinical trials in asthma. Lancet, 1956; 271: 803-806.
  102. Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J. 1972; 1: 585-90.
  103. CONTROLLED trial of effects of cortisone acetate in status asthmaticus; report to the Medical Research Council by the subcommittee on clinical trials in asthma. Lancet. 1956; 271: 803-6.
  104. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. European Journal of Respiratory Diseases. Supplement. 1982 122 (suppl): 86-95.
  105. Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev. 2008; 8: CD003135.
  106. Cowie RL, Giembycz MA, Leigh R. Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children. Expert Opin Pharmacother. 2009; 10: 2009-14.
  107. Korenblat PE. Ciclesonide and the treatment of asthma. Expert Opin Pharmacother. 2010; 11: 463-79.
  108. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med. 2003; 139: 359-70.
  109. Baptist AP, Reddy RC. Inhaled corticosteroids for asthma: are they all the same? J Clin Pharm Ther. 2009; 34: 1-12.
  110. Maryslone JF. Barrett-Connor El., Vlorton DJ Inhaled and oral corticosteroids: their effects on bone nnnerul density in oldcr adults. Am J Public Health 1995: 85: 1693-5.
  111. Lau E, Mamdani M, Tu K. Inhaled or systemic corticosteroids and the risk of hospitalization for hip fracture among elderly women. Am J Med. 2003; 114: 142-5.
  112. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med. 2004 Jan 1;169(1):83-8.
  113. Bernstein DI, Allen DB. Evaluation of tests of hypothalamic-pituitary-adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2007; 98: 118-27.
  114. Campbell IA, Douglas JG, Francis RM, Prescott RJ, Reid DM; Research Committee of the British Thoracic Society. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax. 2004; 59: 761-8.
  115. Kasayama S, Fujita M, Goya K, Yamamoto H, Fujita K, Morimoto Y, Kawase I, Miyatake A. Effects of alendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticosteroids. Metabolism. 2005; 54: 85-90.
  116. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997; 337: 8-14.
  117. Ernst P, Baltzan M, Deschênes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J. 2006; 27: 1168-74.
  118. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997; 277: 722-7.
  119. Mitchell P, Cumming RG, Mackey DA. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology. 1999; 106: 2301-6.
  120. Minette PA, Barnes PJ. Prejunctional inhibitory muscarinic receptors on cholinergic nerves in human and guinea pig airways. J Appl Physiol. 1988; 64: 2532-7.
  121. Cox JS. Disodium cromoglycate (FPL 670) ('Intal'): a specific inhibitor of reaginic antibody-antigen mechanisms. Nature. 1967; 216: 1328-9.
  122. Rodrigo G. Asthma in adults (acute). Clin Evid (Online). 2011 Apr 4; 2011.
  123. Ogoda M, Niiya R, Koshika T, Yamada S. Comparative characterization of lung muscarinic receptor binding after intratracheal administration of tiotropium, ipratropium, and glycopyrrolate. J Pharmacol Sci. 2011; 115: 374-82.
  124. Sin DD, Tu JV. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease. Thorax. 2000;55: 194-7.
  125. Newnham DM. Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. Drug Saf. 2001; 24: 1065-80.
  126. Fernández-Barrientos Y, Jiménez-Santos M, Martínez-de-la-Casa JM, Méndez- Hernández C, García-Feijoó J. [Acute angle-closure glaucoma resulting from treatment with nebulised bronchodilators]. Arch Soc Esp Oftalmol. 2006; 81: 657-60.
  127. Collier JG, Dornhorst AC. Evidence for two different types of beta-receptors in man. Nature. 1969; 223: 1283-4.
  128. Cullum VA, Farmer JB, Jack D, Levy GP. Salbutamol: a new, selective beta- adrenoceptive receptor stimulant. Br J Pharmacol. 1969; 35: 141-51.
  129. Di Lorenzo G, Morici G, Norrito F, Mansueto P, Melluso M, Purello D'Ambrosio F, Barbagallo Sangiorgi G. Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics. Clin Exp Allergy. 1995; 25: 951-6.
  130. Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, Johnson M, Lunts LH, Nials AT, Sheldrick KE, Skidmore IF. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol. 1991;104: 665-71.
  131. Anderson GP. Pharmacology of formoterol: an innovative bronchodilator. Agents Actions Suppl. 1991;34: 97-115.
  132. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2- agonists and corticosteroids. Eur Respir J. 2002; 19: 182-91.
  133. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008; 155: 291-9.
  134. Persson CG. On the medical history of xanthines and other remedies for asthma: a tribute to HH Salter. Thorax. 1985; 40: 881-6.
  135. Jenne JW. What role for theophylline therapy? Thorax. 1994;49:97-100.
  136. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002; 99: 8921-6.
  137. Curry JJ. The action of histamine on the respiratory tract in normal and asthmatic subjects. J Clin Invest. 1946; 25: 785-91.
  138. Van Cauwenberge P. Advances in allergy management. Allergy. 2002; 57 (Suppl 75):29-36.
  139. D a h l é n S E , H e d q v i s t P , H a m m a r s t r ö m S , Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980; 288: 484-6.
  140. Adelroth E, Morris MM, Hargreave FE, O'Byrne PM. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med. 1986; 315: 480-4.
  141. Davidson AB, Lee TH, Scanlon PD, Solway J, McFadden ER Jr, Ingram RH Jr, Corey EJ, Austen KF, Drazen JM. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. Am Rev Respir Dis. 1987; 135: 333-7.
  142. Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J. 1995; 8: 1203-13.
  143. Smith CM, Hawksworth RJ, Thien FC, Christie PE, Lee TH. Urinary leukotriene E4 in bronchial asthma. Eur Respir J. 1992; 5:693-9.
  144. D'Urzo AD, Chapman KR. Leukotriene-receptor antagonists. Role in asthma management. Can Fam Physician. 2000; 46: 872-9.
  145. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Bernstein DI, Blessing-Moore J, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011; 127 (1 Suppl): S1-55.
  146. Asero R. Efficacy of injection immunotherapy with ragweed and birch pollen in elderly patients. Int Arch Allergy Immunol. 2004; 135: 332-5.
  147. Eidelman F, Darzentas N. Efficacy of Allergy Immunotherapy in the Elderly. J Allergy Clin Immunol 2000; 105 (suppl 1): s 313.